SP-0202 (GBP410): A 21-Valent Pneumococcal Conjugate Vaccine Candidate

1. Introduction

1.1 Overview of SP-0202 (GBP410)

SP-0202 is an investigational 21-valent pneumococcal conjugate vaccine (PCV21) candidate currently in late-stage clinical development.[1] Also identified by the development code GBP410, and sometimes referred to as "Next Gen PCV - Sanofi" or "Next-generation pneumococcal conjugate vaccine - Sanofi/SK Bioscience", this vaccine aims to prevent invasive pneumococcal disease (IPD) and other infections caused by the bacterium Streptococcus pneumoniae.[2] Pneumococcal infections, including pneumonia, meningitis, sepsis, and otitis media, represent a significant global health burden, particularly affecting young children and older adults.[4] Existing pneumococcal vaccines have substantially reduced disease incidence, but the emergence of non-vaccine serotypes and the desire for broader protection drive the development of next-generation vaccines like SP-0202/GBP410.[4] By incorporating antigens against 21 distinct pneumococcal serotypes, SP-0202/GBP410 seeks to offer expanded protection compared to currently available vaccines.[1]

1.2 Developers and Collaboration

The development of SP-0202/GBP410 is a collaborative effort between Sanofi (including its vaccine division, Sanofi Pasteur) and SK Bioscience (including SK Chemicals).[2] This partnership represents a significant strategic alliance, extending beyond this specific vaccine candidate to encompass the co-development of next-generation pneumococcal vaccines.[5] The collaboration structure leverages the complementary strengths of both organizations: SK Bioscience provides advanced manufacturing capabilities, notably its L HOUSE facility which is being expanded to meet cGMP standards for global supply, while Sanofi contributes its extensive expertise in vaccine research and development, along with its established global commercialization infrastructure.[5] The commercialization agreement stipulates that SK Bioscience will hold exclusive rights in South Korea, whereas Sanofi will manage commercialization in all other global markets, with SK Bioscience receiving royalties on these international sales.[5] This integrated partnership model is designed to optimize both the efficiency of the vaccine's development pathway and its potential reach upon successful approval.

1.3 Rationale and Unmet Need

Streptococcus pneumoniae remains a leading cause of vaccine-preventable morbidity and mortality worldwide, especially among children under five years old.[4] While the introduction of pneumococcal conjugate vaccines (PCVs) has significantly reduced the burden of IPD caused by vaccine-included serotypes, challenges remain. One key issue is serotype replacement, where non-vaccine serotypes emerge and increase in prevalence, potentially diminishing the overall public health impact of vaccination programs.[6] Current licensed PCVs cover up to 20 serotypes. SP-0202/GBP410, with its 21-valent formulation, is being developed specifically to address this unmet need by providing broader serotype coverage.[1] The inclusion of additional serotypes aims to offer enhanced protection against the circulating strains responsible for a significant portion of remaining pneumococcal disease, positioning SP-0202/GBP410 as a potential advancement over existing vaccine options.[3]

2. Mechanism of Action and Vaccine Design

2.1 Vaccine Class and Technology

SP-0202/GBP410 is classified as a pneumococcal conjugate vaccine (PCV).[1] This vaccine technology involves chemically linking (conjugating) purified capsular polysaccharides (PS) from specific S. pneumoniae serotypes to a carrier protein.[1] Capsular polysaccharides alone are T-independent antigens, which typically elicit a poor immune response, particularly in infants whose immune systems are still developing, and do not induce immunological memory.[4] By conjugating these polysaccharides to a carrier protein, the vaccine converts the immune response to a T-dependent one. This process engages T-helper cells, leading to a more robust and durable immune response, including the generation of memory B-cells, which is crucial for long-term protection and effective booster responses.[11] This conjugate technology is well-established as providing effective protection against pneumococcal infections.[1] Sanofi has indicated that SP-0202/GBP410 utilizes an "innovative carrier" protein, suggesting a potential technological refinement that may facilitate the inclusion of a higher number of serotypes (21-valent) without compromising the immune response to individual components, effectively "breaking the glass ceiling of serotype compositions".[1]

2.2 Immunological Action

As an immunostimulant, SP-0202/GBP410 is designed to provoke a protective immune response against the 21 pneumococcal serotypes included in its formulation.[2] Upon administration, the vaccine presents the conjugated polysaccharide antigens to the immune system. The T-dependent response elicited leads to the production of serotype-specific immunoglobulin G (IgG) antibodies.[4] These antibodies are critical for protection against pneumococcal disease. They bind to the bacterial capsule, promoting opsonization – the process of marking bacteria for destruction by phagocytic immune cells.[4] This antibody binding also facilitates complement-dependent phagocytosis, further enhancing bacterial clearance.[4] Clinical trials for pneumococcal vaccines routinely measure the levels of serotype-specific IgG antibodies and their functional capacity using the opsonophagocytic assay (OPA), as these are considered key correlates of protection against IPD.[14]

2.3 Valency and Serotype Coverage

SP-0202/GBP410 is a 21-valent vaccine, meaning it targets 21 distinct serotypes of S. pneumoniae.[1] This represents a higher valency compared to currently licensed PCVs such as the 13-valent (PCV13, Prevnar 13) and 20-valent (PCV20, Prevnar 20) vaccines, which were used as comparators in its clinical trials.[1] The development strategy explicitly aims to provide broader serotype coverage, potentially protecting against a larger proportion of circulating disease-causing strains.[1] It is noted as the first PCV candidate with more than 20 serotypes to advance into Phase III clinical trials in infants and toddlers.[5]

The pursuit of higher valency reflects a competitive dynamic within the PCV market, where expanded serotype coverage is a primary differentiator. While adding more serotypes offers the potential for broader protection, it also presents technical challenges. Ensuring a robust and balanced immune response to each individual serotype without significant immunological interference between the different antigens is crucial. Furthermore, the clinical relevance of the additional serotypes included must be demonstrated, ideally targeting strains currently responsible for significant disease burden or those emerging due to serotype replacement following the widespread use of lower-valent PCVs. The ongoing Phase III program is designed to rigorously evaluate whether SP-0202/GBP410 successfully overcomes these challenges and delivers on its promise of broader, effective protection.[5]

3. Clinical Development Program

3.1 Preclinical Development

The provided documentation does not contain specific details regarding the preclinical evaluation of SP-0202/GBP410, such as results from animal immunogenicity or toxicology studies.[7] However, the progression into large-scale human trials implies that the vaccine candidate successfully met preclinical safety and immunogenicity criteria based on established principles for conjugate vaccine development. Preclinical work likely involved standard in vitro characterization and in vivo studies in relevant animal models to confirm the vaccine's ability to elicit immune responses against the targeted serotypes and to establish an initial safety profile before human testing commenced.[6]

3.2 Phase II Clinical Trials

The Phase II program for SP-0202/GBP410 involved studies in both pediatric and adult populations to assess initial safety and immunogenicity.

Infant/Toddler Study:

A key Phase II study, initiated in May 2020 across sites in the United States, Canada, and Honduras, evaluated SP-0202/GBP410 in infants and toddlers.1 This randomized, controlled trial enrolled 712 infants (aged 42-89 days at entry) and 140 toddlers (aged 12-15 months at entry).1 Infants received a primary vaccination series at approximately 2, 4, and 6 months of age, while toddlers, who had previously received three doses of PCV13, received a single booster dose.1 The study compared formulations of SP-0202/GBP410 against the licensed 13-valent vaccine, Prevnar 13, as the active control.1 An important aspect was the assessment of co-administration with other routine pediatric vaccines (including DTaP, IPV, Hib, rotavirus, Hepatitis B, MMR, and varicella vaccines).1

Positive results from this trial were announced in June 2023.[8] The study demonstrated that SP-0202/GBP410 elicited immune responses (measured by serotype-specific IgG concentrations and OPA titers) comparable to those induced by Prevnar 13 after both the primary infant series and the toddler booster dose.[1] The safety profile was reported as favorable and well-tolerated, with a reactogenicity profile similar to the control vaccine, and no vaccine-related serious adverse events were observed.[1] Crucially, co-administration analyses indicated that SP-0202/GBP410 did not interfere with the immunogenicity or safety of the concurrently administered routine pediatric vaccines.[1] These positive Phase II findings in the target pediatric population were foundational for the decision to proceed to Phase III development.[1]

Adult Study (NCT04583618):

A separate Phase II trial (NCT04583618) was conducted in the US to evaluate the safety and immunogenicity of SP-0202 in 750 healthy adults aged 50-84 years.15 This randomized, observer-blind study compared three different formulations of SP-0202 (designated IIb, VI, and VII) administered as a single intramuscular dose against both Prevnar 13 and the 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax 23).15 The primary outcomes focused on safety (adverse events) and immunogenicity (OPA titers and IgG concentrations) measured 30 days post-vaccination.15 While the protocol and statistical analysis plan for this study are available, the results have not been detailed in the provided sources.21

Table 1: Summary of Key Phase II Trial Results (GBP410/SP0202)

Population	Comparator	Key Immunogenicity Finding	Key Safety Finding	Snippet IDs
Infants/Toddlers	Prevnar 13®	Comparable immunogenicity (IgG/OPA) after primary and booster doses	Well-tolerated; Comparable reactogenicity to control; No vaccine-related SAEs	1
Adults (50-84 yrs)	Prevnar 13®, Pneumovax 23®	Results not detailed in provided sources	Results not detailed in provided sources	15

3.3 Phase III Clinical Program

Based on the encouraging Phase II results, particularly in infants, a large-scale global Phase III program for SP-0202/GBP410 was initiated.[5]

Overview and Initiation: The program aims to definitively establish the efficacy, safety, and immunogenicity of the vaccine in a broad pediatric and adolescent population, generating the data required for regulatory submissions worldwide.[5] The first participant in the Phase III program was dosed in December 2024 in Australia.[5] Regulatory processes are advancing, with the US FDA having reviewed the Investigational New Drug (IND) amendment for the Phase III studies, and approval also granted by the Australian Human Research Ethics Committee (HREC).[5]

Scope and Design: This extensive program plans to enroll over 7,700 participants, ranging in age from 6 weeks to 17 years.[5] The trials are randomized, typically employing a modified double-blind design and using an active comparator, notably the licensed 20-valent PCV (Prevnar 20), reflecting the current standard of care in many regions.[16] Participants will receive up to four doses depending on their age at enrollment.[5] The program has a global footprint, with studies planned or ongoing in the US, Europe, Australia, Asia, Latin America, Honduras, and Puerto Rico.[16] The comprehensive nature of this program, including its large sample size, broad age range, global reach, and use of an active comparator, underscores the commitment to generating a robust data package suitable for major regulatory agencies.

Key Trials: Two specific Phase III trials are identified in the documentation:

• NCT06824181: This recruiting study investigates mixed vaccination schedules, comparing sequences involving PCV21 (SP0202) and PCV20 (Prevnar 20) in healthy infants and toddlers (target enrollment 515).[2] The inclusion of mixed schedules addresses practical questions regarding the integration of a new vaccine into existing immunization programs, a critical factor for public health implementation.
• NCT06824194: This recruiting study focuses specifically on the safety profile of PCV21 compared to PCV20 in healthy infants aged 42-89 days.[2]

Primary Objective and Timelines: The primary objective across the Phase III program is generally to demonstrate non-inferiority or superiority of the immune response (OPA/IgG) generated by SP-0202/GBP410 compared to the active comparator (PCV20), alongside a thorough evaluation of safety.[16] The program is projected to be completed, with final data expected, in 2027.[1]

Table 2: Overview of Key Phase III Clinical Trials (GBP410/SP0202)

NCT ID	Status	Phase	Target Population (Age)	Enrollment	Purpose/Key Endpoints	Locations (Examples)	Snippet IDs
NCT06824181	Recruiting	3	Infants/Toddlers (42d - 15mo)	515	Assess safety & immunogenicity of mixed PCV21/PCV20 schedules	US, Europe, Asia, LatAm	2
NCT06824194	Recruiting	3	Infants (42d - 89d)	N/A	Document safety profile of PCV21 compared to PCV20	US, Honduras, Puerto Rico	2

4. Manufacturing and Supply Strategy

4.1 Manufacturing Facility

The primary manufacturing site designated for SP-0202/GBP410 production is SK Bioscience's L HOUSE facility, located in Andong, South Korea.[5] This facility is central to the collaboration's strategy for ensuring vaccine supply.

4.2 Facility Expansion and Investment

Recognizing the potential global demand for a successful higher-valent PCV, Sanofi and SK Bioscience initiated a significant expansion of the L HOUSE facility in March 2024.[5] This expansion, involving a joint financial investment from both partners, aims to add substantial manufacturing capacity (approx. 4,200 sq meters mentioned in one source).[17] A key objective of this expansion is to ensure the new facilities comply with the US FDA's current Good Manufacturing Practice (cGMP) standards, a prerequisite for supplying the US and other major international markets.[5]

4.3 Strategic Importance

The decision to invest heavily in manufacturing capacity expansion concurrently with the ongoing Phase III trials signifies a strong commitment and confidence from both Sanofi and SK Bioscience in the potential of SP-0202/GBP410. This proactive approach aims to mitigate potential manufacturing bottlenecks and de-risk the commercial launch timeline, ensuring that large-scale, global supply can be readily available if the vaccine receives regulatory approval following the completion of the Phase III program.[5] Establishing cGMP-compliant production lines well in advance is a critical step for facilitating entry into key markets like the US and Europe.[5]

5. Regulatory Pathway and Outlook

5.1 Current Status

SP-0202/GBP410 has successfully completed Phase II clinical trials, demonstrating positive safety and immunogenicity results in the target infant and toddler populations.[1] The vaccine candidate is currently progressing through a comprehensive global Phase III program.[2] Key regulatory milestones achieved include the US FDA's review of the IND amendment permitting the initiation of Phase III studies and approval from the Australian HREC.[5]

5.2 Anticipated Timelines

The ongoing Phase III program is expected to yield final data in 2027.[1] Contingent upon positive results from these pivotal trials, Sanofi and SK Bioscience plan to submit applications for marketing authorization to major regulatory agencies, including the FDA and EMA, targeting the year 2027.[5]

5.3 Regulatory Designations

Based on the information available in the provided sources, there is no indication that SP-0202/GBP410 has been granted any expedited regulatory designations by the FDA (such as Fast Track or Breakthrough Therapy) or the EMA (such as PRIME).[35] While these pathways exist to accelerate the development and review of therapies addressing significant unmet needs, their absence for SP-0202/GBP410 suggests the development is likely proceeding along a standard regulatory timeline. The strategy appears reliant on the comprehensive data package generated from the large-scale Phase III program to demonstrate the vaccine's value, primarily through its broader serotype coverage compared to existing options, rather than qualifying for pathways typically reserved for first-in-class therapies or those showing dramatic improvements over available treatments in preliminary stages. Furthermore, the vaccine is not designated as an Orphan Drug, consistent with its intended use for the broad prevention of common pneumococcal infections.[2]

5.4 Market Outlook

The developers, SK Bioscience and Sanofi, have expressed significant optimism regarding the commercial prospects of SP-0202/GBP410, citing its "blockbuster potential" following positive Phase II results.[8] The primary driver for this outlook is the vaccine's 21-valent formulation, which is anticipated to offer broader serotype coverage than existing market-leading PCVs.[1] The expectation is that this broader coverage, combined with Sanofi's established global marketing infrastructure and expertise in the pediatric vaccine market, will enable SP-0202/GBP410 to capture a significant market share rapidly upon potential approval and commercialization.[1] The pneumococcal vaccine market is substantial and growing, further supporting the potential commercial value of a successful next-generation candidate.[17]

6. Conclusion

6.1 Summary of Development

SP-0202/GBP410 is a 21-valent pneumococcal conjugate vaccine candidate emerging from a strategic collaboration between Sanofi and SK Bioscience. Following successful Phase II trials that demonstrated comparable immunogenicity and a favorable safety profile relative to existing vaccines in infants and toddlers, the program has advanced into a large, global Phase III clinical evaluation.[1] This pivotal phase, involving over 7,700 participants across a wide pediatric age range, is designed to provide robust data on safety and efficacy against an active comparator (PCV20).[5] Concurrently, significant investments are being made in expanding dedicated manufacturing capacity at SK Bioscience's L HOUSE facility to prepare for potential global supply.[5]

6.2 Potential Impact

The primary potential impact of SP-0202/GBP410 lies in its higher valency. By targeting 21 pneumococcal serotypes, it aims to offer broader protection against Streptococcus pneumoniae infections than currently available conjugate vaccines.[1] If the Phase III program confirms its efficacy and safety, SP-0202/GBP410 could represent a significant advancement in pneumococcal disease prevention, potentially addressing issues related to serotype replacement and offering enhanced protection for vulnerable pediatric populations worldwide.

6.3 Future Directions

The future trajectory of SP-0202/GBP410 hinges on the outcomes of the ongoing Phase III clinical program, with final data anticipated in 2027.[1] Successful completion of these trials, demonstrating non-inferiority or superiority to the PCV20 comparator in terms of immune response and confirming the favorable safety profile, will be critical for subsequent regulatory submissions planned for 2027.[5] The parallel expansion of manufacturing capabilities underscores the developers' commitment to ensuring timely and adequate global access should the vaccine receive approval.[5] The collaboration also extends to the development of further next-generation pneumococcal vaccines, indicating a long-term strategic focus in this therapeutic area.[5]

Works cited

1. PR > 보도자료 > SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate, accessed May 9, 2025, https://www.skbioscience.com/en/news/news_01_01?mode=view&id=217&
2. SP 0202 - AdisInsight, accessed May 9, 2025, https://adisinsight.springer.com/drugs/800040263
3. SP 0202 | Next Generation Pneumococcal Conjugate Vaccine, accessed May 9, 2025, https://ontosight.ai/glossary/term/next-generation-pneumococcal-conjugate-vaccine--67a0ddae6c3593987a5057b9
4. Serotype-independent pneumococcal vaccines - PMC, accessed May 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11113425/
5. PR > 보도자료 > SK bioscience-Sanofi's 21-Valent Pneumococcal Conjugate Vaccine Candidate for Phase 3 Studies IND Amendment Review Completed by U.S. FDA, accessed May 9, 2025, https://www.skbioscience.com/en/news/news_01_01?mode=view&id=288
6. Streptococcus pneumoniae serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy? - PubMed Central, accessed May 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11864319/
7. SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate - BioSpace, accessed May 9, 2025, https://www.biospace.com/sk-bioscience-sanofi-announce-positive-results-from-phase-ii-study-of-21-valent-pneumococcal-conjugate-vaccine-candidate
8. Manufacturing facility expansion to advance next-gen vaccine, accessed May 9, 2025, https://www.europeanpharmaceuticalreview.com/news/220180/manufacturing-facility-expansion-to-advance-next-gen-vaccine/
9. SK bioscience Breaks Ground on Manufacturing Facility Expansion for Extending Product Pipeline - FirstWord Pharma, accessed May 9, 2025, https://firstwordpharma.com/story/5834729
10. PR > 보도자료 > SK bioscience and Sanofi Initiate Submission of ..., accessed May 9, 2025, https://www.skbioscience.com/en/news/news_01_01?mode=view&id=243
11. Pneumococcal vaccine - Wikipedia, accessed May 9, 2025, https://en.wikipedia.org/wiki/Pneumococcal_vaccine
12. 21-Valent Pneumococcal Conjugate Vaccine Candidate Produced Positive Study Results, accessed May 9, 2025, https://www.vax-before-travel.com/2023/06/30/21-valent-pneumococcal-conjugate-vaccine-candidate-produced-positive-study-results
13. SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate - PR Newswire, accessed May 9, 2025, https://www.prnewswire.com/news-releases/sk-bioscience-sanofi-announce-positive-results-from-phase-ii-study-of-21-valent-pneumococcal-conjugate-vaccine-candidate-301867294.html
14. Study of a Pneumococcal Conjugate Vaccine When Administered ..., accessed May 9, 2025, https://www.sanofistudies.com/cwout/CW-V9DEXS//us/en/listing/286375/study-of-a-pneumococcal/
15. cdn.clinicaltrials.gov, accessed May 9, 2025, https://cdn.clinicaltrials.gov/large-docs/18/NCT04583618/SAP_001.pdf
16. Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age - Clinical Trials at UTMB, accessed May 9, 2025, https://utmb.trialstoday.org/trial/NCT06824181
17. SK bioscience, Sanofi win Australian nod for phase 3 study of 21-valent pneumococcal vaccine < Pharma < Article - KBR - Korea Biomed, accessed May 9, 2025, https://www.koreabiomed.com/news/articleView.html?idxno=24374
18. PR > 보도자료 > SK bioscience-Sanofi's 21-Valent Pneumococcal Conjugate Vaccine Candidate for Phase 3 Studies IND Amendment Review Completed by U.S. FDA, accessed May 9, 2025, https://www.skbioscience.com/en/news/news_01_01?mode=view&id=288&
19. Preliminary nonclinical safety and immunogenicity of an rVSV-ΔG-SARS-CoV-2-S vaccine in mice, hamsters, rabbits and pigs - PubMed, accessed May 9, 2025, https://pubmed.ncbi.nlm.nih.gov/35032184/
20. SK bioscience, Sanofi report Phase II pneumococcal vaccine data, accessed May 9, 2025, https://www.clinicaltrialsarena.com/news/sk-bioscience-sanofi-pneumococcal-vaccine/
21. Title Page NCT04583618 - ClinicalTrials.gov, accessed May 9, 2025, https://cdn.clinicaltrials.gov/large-docs/18/NCT04583618/Prot_000.pdf
22. ClinicalTrials.gov: Home, accessed May 9, 2025, https://clinicaltrials.gov/
23. Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies - PMC, accessed May 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10929583/
24. accessed January 1, 1970, https://www.clinicaltrials.gov/study/NCT04583618
25. Sanofi, SK Bioscience Launch Phase III Trial Program to Develop PCV21 for Pneumococcal Conjugate Vaccines - Pharmaceutical Executive, accessed May 9, 2025, https://www.pharmexec.com/view/sanofi-sk-bioscience-launch-phase-iii-trial-program-develop-pcv21-pneumococcal-conjugate-vaccines
26. PR > 보도자료 > SK bioscience Expands L HOUSE for Preparing Commercialization of Next-Generation Pneumococcal Vaccine, accessed May 9, 2025, https://www.skbioscience.com/en/news/news_01_01?mode=view&id=238
27. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT04583618
28. SK bioscience, Sanofi seek FDA nod for phase 3 study of 21-valent pneumococcal conjugate vaccine < Bio < Article - KBR, accessed May 9, 2025, https://www.koreabiomed.com/news/articleView.html?idxno=22751
29. Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age | Clinical Research Trial Listing - CenterWatch, accessed May 9, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06824194/study-of-the-safety-of-a-21-valent-pneumococcal-conjugate-vaccine-in-healthy-infants-from-approximately-2-months-of-age
30. Rotavirus vaccine,live(Merck & Co.) - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 9, 2025, https://synapse.patsnap.com/drug/42ca623d8cda464b967958575d5518be
31. The trial - ClinicalTrials.gov, accessed May 9, 2025, https://clinicaltrials.gov/study/NCT02945475
32. accessed January 1, 1970, https://www.clinicaltrials.gov/study/NCT06824181
33. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT06824181
34. SK bioscience and Sanofi's GBP410 vaccine enters global Phase III trials - Patrick Wareing, accessed May 9, 2025, https://patrickwareing.com/news/sk-bioscience-and-sanofis-gbp410-vaccine-enters-global-phase-iii-trials/
35. U.S. FDA Approves PREVNAR 20®, Pfizer's 20-valent Pneumococcal Conjugate Vaccine for Infants and Children, accessed May 9, 2025, https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20r-pfizers-20-valent-pneumococcal
36. EU Risk Management Plan for Spikevax, Spikevax bivalent Original/Omicron BA.1, Spikevax bivalent Original - European Medicines Agency, accessed May 9, 2025, https://www.ema.europa.eu/en/documents/rmp/spikevax-previously-covid-19-vaccine-moderna-epar-risk-management-plan_en.pdf
37. European Commission (EC) Approves Merck's CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults - Merck.com, accessed May 9, 2025, https://www.merck.com/news/european-commission-ec-approves-mercks-capvaxive-pneumococcal-21-valent-conjugate-vaccine-for-prevention-of-invasive-pneumococcal-disease-and-pneumococcal-pneumonia-in-adults/
38. Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults - Merck.com, accessed May 9, 2025, https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-capvaxive-pneumococcal-21-valent-conjugate-vaccine-for-pneumococcal-vaccination-in-adults/
39. Chlamydia vaccine candidate granted fast track designation by the US FDA - Sanofi US News, accessed May 9, 2025, https://www.news.sanofi.us/2025-03-26-Chlamydia-vaccine-candidate-granted-fast-track-designation-by-the-US-FDA
40. FDA grants Fast Track designation to Sanofi's mRNA chlamydia vaccine, accessed May 9, 2025, https://www.eatg.org/hiv-news/fda-grants-fast-track-designation-to-sanofis-mrna-chlamydia-vaccine/
41. Fabhalta - opinion on variation to marketing authorisation | European Medicines Agency (EMA), accessed May 9, 2025, https://www.ema.europa.eu/en/medicines/human/variation/fabhalta
42. PRIME: priority medicines | European Medicines Agency (EMA) - European Union, accessed May 9, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines